The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Ki67 targeted strategies for cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Ki67 is a promising molecular target in the diagnosis of cancer (Review)
LI, L. T., JIANG, G., CHEN, Q., & ZHENG, J. N. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2914 · Cited by 859
Self-citationMicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Cheng, C. J., Bahal, R., Babar, I. A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D. T., Glazer, P. M., Engelman, D. M., et al. (2015) · Nature · doi:10.1038/nature13905 · Cited by 823
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Schlüter, C., Duchrow, M., Wohlenberg, C., Becker, M. H., Key, G., Flad, H. D., & Gerdes, J. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.3.513 · Cited by 765
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
Antisense and Antigene Properties of Peptide Nucleic Acids
Hanvey, J. C., Peffer, N. J., Bisi, J. E., Thomson, S. A., Cadilla, R., Josey, J. A., Ricca, D. J., Hassman, C. F., Bonham, M. A., Au, K. G., et al. (1992) · Science · doi:10.1126/science.1279811 · Cited by 533
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., & Thornton, C. A. (2012) · Nature · doi:10.1038/nature11362 · Cited by 502
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Telomerase therapeutics for cancer: challenges and new directions
Shay, J. W., & Wright, W. E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2081 · Cited by 432
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Monteleone, G., Neurath, M. F., Ardizzone, S., Di Sabatino, A., Fantini, M. C., Castiglione, F., Scribano, M. L., Armuzzi, A., Caprioli, F., Sturniolo, G. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407250 · Cited by 401
Inhibition of human telomerase activity by peptide nucleic acids
Norton, J. C., Piatyszek, M. A., Wright, W. E., Shay, J. W., & Corey, D. R. (1996) · Nature Biotechnology · doi:10.1038/nbt0596-615 · Cited by 343
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C. C., Uprichard, M. J., Hatfield, M. J., et al. (2002) · PubMed · Cited by 309
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
RNAi Therapies: Drugging the Undruggable
Wu, S. Y., Lopez-Berestein, G., Calin, G. A., & Sood, A. K. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008362 · Cited by 273
Nemunaitis, J., Tong, A. W., Nemunaitis, M., Senzer, N., Phadke, A. P., Bedell, C., Adams, N., Zhang, Y.-A., Maples, P. B., Chen, S., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.262 · Cited by 265
Verheijen, R., Kuijpers, H. J. H., Schlingemann, R. O., Boehmer, A. L. M., Driel, R. V., Brakenhoff, G. J., & Ramaekers, F. C. S. (1989) · Journal of Cell Science · doi:10.1242/jcs.92.1.123 · Cited by 222
Chlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G., Burstein, H. J., Eisen, A., Lipkus, I., & Pfister, D. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.029 · Cited by 197
Thermodynamics of Sequence-Specific Binding of PNA to DNA
Ratilainen, T., Holmén, A., Tuite, E., Nielsen, P. E., & Nordén, B. (2000) · Biochemistry · doi:10.1021/bi000039g · Cited by 192
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Kanerva, A., Nokisalmi, P., Diaconu, I., Koski, A., Cerullo, V., Liikanen, I., Tähtinen, S., Oksanen, M., Heiskanen, R., Pesonen, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2546 · Cited by 177
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu, D., Chen, Y., Dilley, J., Li, Y., Embry, M. G., Zhang, H., Nguyen, N. N. M., Amin, P., Oh, J., & Henderson, D. (2001) · PubMed · Cited by 173
Liikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.51 · Cited by 165
Blancato, J., Singh, B., Liu, A., Liao, D. J., & Dickson, R. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601703 · Cited by 160
Evolution of oncolytic adenovirus for cancer treatment
Choi, J.-W., Lee, J. S., Kim, S. W., & Yun, C. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.011 · Cited by 144
Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas
Karamitopoulou, E., Perentes, E., Tolnay, M., & Probst, A. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90224-6 · Cited by 137
Rioux-Leclercq, N. C., Turlin, B., Bansard, J., Patard, J., Manunta, A. F., Moulinoux, J.-P., Guillé, F., Ramée, M. P., & Lobel, B. (2000) · Urology · doi:10.1016/s0090-4295(99)00550-6 · Cited by 129
Li, J., Liu, H., Xr, Z., Xu, J.-P., Hu, W.-K., Liang, M., Chen, S.-Y., Hu, F., & Chu, D.-T. (2008) · Gene Therapy · doi:10.1038/gt.2008.179 · Cited by 122
Contemporary Management of Adrenocortical Carcinoma
Zini, L., Porpiglia, F., & Faßnacht, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.062 · Cited by 117
Delivery Systems and Local Administration Routes for Therapeutic siRNA
Vicentini, F. T. M. C., Borgheti-Cardoso, L. N., Depieri, L. V., Mano, D. D. M., Abelha, T. F., Petrilli, R., & Bentley, M. V. L. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0971-1 · Cited by 115
Potential clinical applications of siRNA technique: benefits and limitations
Chen, S., & Zhaori, G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02400.x · Cited by 107
Zhou, Y., Zhang, C., & Liang, W. P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.044 · Cited by 103
Ki‐67 labeling in postmitotic cells defines different Ki‐67 pathways within the 2c compartment
du Manoir, S., Guillaud, P., Camus, E., Seigneurin, D., & Brugal, G. (1991) · Cytometry · doi:10.1002/cyto.990120511 · Cited by 102
Nemunaitis, J. J., Cunningham, C., Tong, A. W., Post, L. E., Netto, G. J., Paulson, A. S., Rich, D., Blackburn, A., Sands, B. E., Gibson, B., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700585 · Cited by 97
Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers
Geyer, F. C., Rodrigues, D. N., Weigelt, B., & Reis-Filho, J. S. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31823fafa0 · Cited by 94
The Business of RNAi Therapeutics in 2012
Haussecker, D. (2012) · Molecular Therapy: Nucleic Acids · doi:10.1038/mtna.2011.9 · Cited by 93
Laskin, J. J., Nicholas, G. A., Lee, C., Gitlitz, B. J., Vincent, M. D., Cormier, Y. F., Stephenson, J., Ung, Y., Sanborn, R. E., Pressnail, B., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823f459c · Cited by 90
Freytag, S. O., Stricker, H. J., Lü, M., Elshaikh, M. A., Aref, I., Pradhan, D. R., Levin, K. J., Kim, J. H., Peabody, J. O., Siddiqui, F., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.02.034 · Cited by 89
Antisense treatment against Ki‐67 mRNA inhibits proliferation and tumor growth in vitro and in vivo
Kausch, I., Lingnau, A., Endl, E., Sellmann, K., DEINERT, I., Ratliff, T. L., Jocham, D., Sczakiel, G., Gerdes, J., & Andreas Böhle, E. (2003) · International Journal of Cancer · doi:10.1002/ijc.11111 · Cited by 88
Duchrow, M., Schlüter, C., Wohlenberg, C., Flad, H. D., & Gerdes, J. (1996) · Cell Proliferation · doi:10.1046/j.1365-2184.1996.d01-2.x · Cited by 83
The future of antisense therapy: combination with anticancer treatments
Biroccio, A., Leonetti, C., & Zupi, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206812 · Cited by 80
Small interfering RNA for experimental cancer therapy.
Tong, A. W., Zhang, Y., & Nemunaitis, J. J. (2005) · PubMed · Cited by 78
Viruses – seeking and destroying the tumor program
O’Shea, C. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209047 · Cited by 73
Tumor‐Targeting Multifunctional Nanoparticles for siRNA Delivery: Recent Advances in Cancer Therapy
Ku, S. H., Kim, K., Choi, K., Kim, S. H., & Kwon, I. C. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300607 · Cited by 72
Conde, J., Edelman, E. R., & Artzi, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.003 · Cited by 72
Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides
Sepp‐Lorenzino, L., & Ruddy, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.174 · Cited by 69
Wyatt, C. A., Geoghegan, J. C., & Brinckerhoff, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2446 · Cited by 69
Are RNAi and miRNA therapeutics truly dead?
Conde, J., & Artzi, N. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.12.005 · Cited by 63
Ibrahim, T., Farolfi, A., Scarpi, E., Mercatali, L., Medri, L., Ricci, M., Nanni, O., Serra, L., & Amadori, D. (2012) · Oncology · doi:10.1159/000345795 · Cited by 62
Chemotherapy Induces Oral Mucositis in Mice Without Additional Noxious Stimuli
Bertolini, M., Sobue, T., Thompson, A. K., & Dongari‐Bagtzoglou, A. I. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.05.001 · Cited by 59
Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models
Thomas, S. M., Sahu, B., Rapireddy, S., Bahal, R., Wheeler, S., Procopio, E. M., Kim, J., Joyce, S. C., Contrucci, S., Wang, Y., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3003946 · Cited by 53
Natale, R. B., Blackhall, F. H., Kowalski, D. M., Ramlau, R., Bepler, G., Grossi, F., Lerchenmuller, C. A., Pinder-Schenck, M. C., Mezger, J. M., Danson, S. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000285 · Cited by 48
Zheng, J., Teng-xiang, M., Cao, J., Sun, X., Chen, J., Li, W., Wen, R.-M., Sun, Y., & Pei, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.064 · Cited by 46
Self-citationIncreasing the Efficacy of Oncolytic Adenovirus Vectors
Tóth, K., & Wold, W. S. M. (2010) · Viruses · doi:10.3390/v2091844 · Cited by 45
Rajecki, M., Kanerva, A., Stenman, U., Tenhunen, M., Kangasniemi, L., Särkioja, M., Ala‐Opas, M., Alfthan, H. V., Sankila, A., Rintala, E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0403 · Cited by 44
Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells
Isola, J. J., Helin, H., & Kallioniemi, O. (1990) · The Histochemical Journal · doi:10.1007/bf01007235 · Cited by 41
The antitumor effects of oncolytic adenovirus H101 against lung cancer
Lei, J., Li, Q., Yang, J.-L., LIU, F., Wang, L., Xu, W., & Zhao, W. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3045 · Cited by 37
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Kennedy, B. W. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1504845 · Cited by 34
A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression
Tian, H., Qian, G., Li, W., Chen, F., Di, J., Zhang, B., Pei, D., Ma, P., & Zheng, J. (2010) · Tumor Biology · doi:10.1007/s13277-010-0119-4 · Cited by 30
Self-citationEffects of the Ad5 upstream E1 region and gene products on heterologous promoters
Hoffmann, D., Jogler, C., & Wildner, O. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.771 · Cited by 23
p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells
Wang, M., Pei, D., Qian, G., Yin, X., Cheng, Q., Li, L., Li, H., & Zheng, J. (2011) · Tumor Biology · doi:10.1007/s13277-011-0191-4 · Cited by 18
Self-citationshRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy
Zhang, J., Ding, M., Xu, K., Mao, L., & Zheng, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8035 · Cited by 15
Self-citationJiang, G., Yang, C.-S., Xu, D., Sun, C., Zheng, J.-N., Lei, T., & Liu, Y.-Q. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.177 · Cited by 14
Self-citation
Metadata
- Authors
- Yang, C., Zhang, J., Ding, M., Xu, K., Li, L., Mao, L., & Zheng, J.
- Venue
- Clinical and Translational Oncology
- Published
- 2017-10-20
- Volume
- 20
- Issue
- 5
- Pages
- 570-575
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- OpenAlex
- W2767185612
- Cited by
- 254
- References
- 71
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.